Τίτλος:
Possible implication of IKAROS gene deletion and BCR-ABL1 variants in progression of chronic myeloid leukemia to lymphoid blast crisis in childhood: A single-institution experience
Γλώσσες Τεκμηρίου:
Αγγλικά
Περίληψη:
Δεν υπάρχει περίληψη
Συγγραφείς:
Moschovi, M.
Adamaki, M.
Athanasiadou, A.
Divane, A.
Karytianou, A.
Tourkantoni, N.
Περιοδικό:
Clinical Lymphoma Myeloma and Leukemia
Εκδότης:
Taylor and Francis Ltd.
Λέξεις-κλειδιά:
BCR ABL 1 protein; BCR ABL protein; Ikaros transcription factor; imatinib; immunoglobulin heavy chain; Janus kinase; recombinase; STAT protein; transcription factor PAX5; unclassified drug; antineoplastic agent; BCR ABL protein; Ikaros transcription factor; protein kinase inhibitor, acute lymphoblastic leukemia; blast cell crisis; bone marrow; cancer growth; cell maturation; childhood leukemia; chronic myeloid leukemia; copy number variation; DNA binding; DNA repair; EBF1 gene; fluorescence in situ hybridization; fusion gene; gene; gene deletion; gene dosage; gene rearrangement; genetic variability; human; IKAROS gene; IKZF1 gene; Letter; leukemia relapse; leukemia remission; minimal residual disease; multiplex ligation dependent probe amplification; PAX5 gene; pre B lymphocyte; priority journal; real time polymerase chain reaction; signal transduction; T lymphocyte receptor gene; blast cell crisis; case report; child; disease course; drug resistance; female; genetic variation; genetics; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; pathology; treatment outcome, Antineoplastic Agents; Blast Crisis; Child; Disease Progression; Drug Resistance, Neoplasm; Female; Fusion Proteins, bcr-abl; Gene Deletion; Genetic Variation; Humans; Ikaros Transcription Factor; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Protein Kinase Inhibitors; Treatment Outcome
DOI:
10.3109/10428194.2014.999331
